Hayashi Paul H, Fontana Robert J
Division of Gastroenterology and Hepatology, University of North Carolina, Chapel Hill, North Carolina.
Division of Gastroenterology, University of Michigan, Ann Arbor, Michigan.
Semin Liver Dis. 2014 May;34(2):134-44. doi: 10.1055/s-0034-1375955. Epub 2014 May 31.
Patients with idiosyncratic drug-induced liver injury (DILI) can pose substantial diagnostic, prognostic, and therapeutic challenges to the practicing gastroenterologist. The presentation of DILI may vary from asymptomatic liver enzyme elevation to acute liver failure. Although most DILI resolves following drug discontinuation, up to 20% of patients progress to chronic DILI further challenging the clinicians diagnostic and management skills. Also, some medications can lead to advanced fibrosis, encephalopathy, and portal hypertension without significant elevation in liver enzymes during exposure. Finally, there are no objective tests to definitively diagnose DILI. Although causality assessment instruments are available, none are widely accepted or used in clinical practice. Therefore, the diagnosis of DILI depends on thorough and accurate history taking, follow-up of the patient's clinical course and excluding more common causes of liver injury. In this review, we discuss the variable clinical presentations, course, and diagnostic methods used to establish a diagnosis and prognosis in DILI.
特异质性药物性肝损伤(DILI)患者会给执业胃肠病学家带来重大的诊断、预后和治疗挑战。DILI的表现可能从无症状的肝酶升高到急性肝衰竭不等。虽然大多数DILI在停药后可缓解,但高达20%的患者会进展为慢性DILI,这进一步考验了临床医生的诊断和管理技能。此外,一些药物在用药期间可导致肝酶无显著升高的情况下出现晚期肝纤维化、脑病和门静脉高压。最后,尚无明确诊断DILI的客观检查方法。虽然有因果关系评估工具,但在临床实践中均未被广泛接受或使用。因此,DILI的诊断依赖于全面、准确的病史采集、对患者临床病程的随访以及排除更常见的肝损伤原因。在本综述中,我们讨论了用于确立DILI诊断和预后的不同临床表现、病程及诊断方法。